National cohort study on liver cirrhosis in Switzerland
SASL Swiss Cirrhosis Cohort Study
This study is tracking patients with liver cirrhosis in Switzerland to gather important information that could help improve treatment and prevent the need for liver transplants.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 10 sites (Lugano, Canton Ticino and 9 other locations) |
| Trial ID | NCT06092385 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to follow patients with liver cirrhosis in Switzerland to collect and analyze a wide range of data, including epidemiological, clinical, histological, psychosocial, and patient-reported outcomes. The study will also biobank biological materials from participants to support future research. By systematically documenting these aspects, the study seeks to understand the disease better and identify potential therapeutic strategies to prevent the need for liver transplantation. The data collected will be used to investigate specific hypotheses related to the progression and management of cirrhosis.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with chronic liver disease who have histologically proven cirrhosis.
Not a fit: Patients under 18 years old or those who have developed liver cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients with liver cirrhosis, potentially reducing the need for liver transplants.
How similar studies have performed: Other studies focusing on cohort data collection for chronic liver diseases have shown promise, indicating that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * A) Patients with chronic liver disease and histologically proven cirrhosis * B) Control subjects with no signs of cirrhosis Exclusion Criteria: * Age \<18 years * patients who developed hepatocellular carcinoma (HCC) and/or cholangiocellular carcinoma (CCC)
Where this trial is running
Lugano, Canton Ticino and 9 other locations
- Gastroenterology and Hepatology, Cantonal Hospital Ticino — Lugano, Canton Ticino, Switzerland (Recruiting)
- University Centre for Gastrointestinal and Liver Diseases, University Hospital Basel, Switzerland — Basel, Switzerland (Recruiting)
- Department of Visceral Surgery and Medicine, University Hospital of Berne — Bern, Switzerland (Not_yet_recruiting)
- Gastroenterology and Hepatology, University Hospital Geneva — Geneva, Switzerland (Not_yet_recruiting)
- Gastroenterology and Hepatology, Lausanne University Hospital — Lausanne, Switzerland (Recruiting)
- Ticino Liver Centre — Lugano, Switzerland (Not_yet_recruiting)
- Gastroenterology and Hepatology, Cantonal Hospital St. Gallen — Sankt Gallen, Switzerland (Not_yet_recruiting)
- Arud Centre for addiction medicine Zurich — Zurich, Switzerland (Not_yet_recruiting)
- Digestive Diseases Insti- tute GastroZentrum, Hirslanden Clinic Zurich — Zurich, Switzerland (Not_yet_recruiting)
- Gastroenterology and Hepatology, University Hospital Zurich — Zurich, Switzerland (Not_yet_recruiting)
Study contacts
- Principal investigator: Christine Bernsmeier, Prof. Dr. med. — University Centre for Gastrointestinal and Liver Diseases, University Hospital Basel, Switzerland
- Study coordinator: Christine Bernsmeier, Prof. Dr. med.
- Email: christine.bernsmeier@clarunis.ch
- Phone: +41 61 265 2525
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.